Viroblock SA Hires Dr. Jamie Paterson as CEO and Closes Financing Round

GENEVA, February 3 - Viroblock SA, a start-up dedicated to developing and
commercializing a new generation of anti-viral products, today announced that
Dr. Jamie Paterson will join Viroblock as Chief Executive Officer (CEO).

Jamie Paterson, a British national, can look back at 20 years of
experience in the pharmaceutical industry. Prior to joining Viroblock he was
Chief Commercial Officer at Neurim Pharmaceuticals. During his 18 years at
Procter & Gamble he held several positions with increasing responsibility
including Marketing Manager Italy and Commercial Director Spain. His final
position at P&G was European Director of Strategic Planning and New Business
Development - Rx & OTC. Jamie holds a PhD in Biochemistry from Imperial
College, University of London.

"I welcome Jamie as our new CEO and I am pleased to concentrate my
activities to further demonstrate scientifically the potential of our
technology in several viral indications" said Thierry Pelet who is one the
co-founders of the company. Thierry will assume the position of Chief Science
Officer (CSO).

Viroblock further announced that it has completed its second round of
equity funding. The Series B financing round was led by Fongit Seed Invest
SA. Peter Pfister, Initiative Capital Romandie SA (managed by DEFI Gestion)
and BlueOcean Ventures acted as co-investors.

"With Jamie and Thierry we have a strong leadership team with
proven business skills and accomplished scientific know-how. This team
equipped with the additional funding can now start developing our first
anti-viral products, which will bring the company to the next level, said
Peter Pfister, Chairman of the Board.

About Viroblock

Viroblock is dedicated to developing and commercializing a new
generation of anti-viral products with a novel mechanism of action against
enveloped viruses. Enveloped viruses represent more than 60% of all existing
viruses and include major human pathogens such as human and avian influenzas,
the hepatitis B and C viruses and the AIDS virus.

Viroblock's unique proprietary products and technologies open
very promising opportunities in a number of prophylactic and therapeutic
applications.

Viroblock was founded in October 2005 by the late Donald
Wallach, a scientist and academic with past tenure at the Harvard Medical
School and Tufts University, and a pioneer in the research of liposome
systems.

    For more information:

    Thierry Pelet
    +41-22-884-8344
    info@viroblock.com

For more information: Thierry Pelet, +41-22-884-8344, info at viroblock.com